Testing a new kidney cancer treatment combined with existing therapy

Plain-English translation of NCT07011719 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called combined with an existing kidney cancer drug called . The study is for people with advanced kidney cancer that has grown or spread despite previous immunotherapy treatment. Researchers want to see if adding this medication helps slow cancer growth better than the existing drug alone.

Currently, some patients with advanced kidney cancer continue to see their cancer progress even after immunotherapy. This trial exists to find out whether this new treatment, when combined with an established therapy, can help patients whose cancer has not responded well to other options.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced or metastatic clear cell renal cell carcinoma (a specific type of kidney cancer) that cannot be surgically removed
your cancer has grown or progressed after you received prior immunotherapy treatment
you have at least one measurable tumor that can be seen on imaging scans
your kidney and liver function are adequate based on recent blood tests
you are in generally good health with a performance status score of 80% or higher

You likely don't qualify if…

you have previously received cabozantinib or a HIF-2α inhibitor
you have another active cancer diagnosed within the past year (except for easily curable local cancers that have been treated)
you are experiencing severe side effects from prior cancer treatment that have not resolved
you have uncontrolled high blood pressure despite being on blood pressure medication
you have a history of leptomeningeal disease or spinal cord compression

What participation looks like

If you join this trial, you will take pills by mouth — either the new medication plus the existing drug, or placebo plus the existing drug. Neither you nor your doctors will initially know which group you're in. You'll have regular clinic visits for blood tests, scans, and check-ups to see how well the treatment is working and to monitor for any side effects. The study involves about 720 patients across multiple sites.

AI-generated summary from trial data · Jul 8, 2026 · Not medical advice

Trial locations(159 sites)

United States

Research Site, Gilbert, Arizona

Research Site, Goodyear, Arizona

Research Site, Phoenix, Arizona

Research Site, Duarte, California

Research Site, Irvine, California